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Abstract
Mainly due to its extremely vulnerable population of critically ill patients, and the high use of (invasive) procedures,
the intensive care unit (ICU) is the epicenter of infections. These infections are associated with an important rise in
morbidity, mortality, and healthcare costs. The additional problem of multidrug-resistant pathogens boosts the
adverse impact of infections in ICUs. Several factors influence the rapid spread of multidrug-resistant pathogens in
the ICU, e.g., new mutations, selection of resistant strains, and suboptimal infection control. Among gram-positive
organisms, the most important resistant microorganisms in the ICU are currently methicillin-resistant Staphylococcus
aureus and vancomycin-resistant enterococci. In gram-negative bacteria, the resistance is mainly due to the rapid
increase of extended-spectrum Beta-lactamases (ESBLs) in Klebsiella pneumonia, Escherichia coli, and Proteus species
and high level third-generation cephalosporin Beta-lactamase resistance among Enterobacter spp. and Citrobacter
spp., and multidrug resistance in Pseudomonas aeruginosa and Acinetobacter species. To conclude, additional efforts
are needed in the future to slow down the emergence of antimicrobial resistance. Constant evaluation of current
practice on basis of trends in MDR and antibiotic consumption patterns is essential to make progress in this
problematic matter.
Introduction - the burden of multidrug resistance
The intensive care unit (ICU) often is called the epicen-
ter of infections, due to its extremely vulnerable popula-
tion (reduced host defences deregulating the immune
responses) and increased risk of becoming infected
through multiple procedures and use of invasive devices
distorting the anatomical integrity-protective barriers of
patients (intubation, mechanical ventilation, vascular
access, etc.). In addition, several drugs may be adminis-
tered, which also predispose for infections, such as
pneumonia, e.g., by reducing the cough and swallow
reflexes (sedatives, muscle relaxants) or by distorting the
normal nonpathogenic bacterial flora (e.g., stress ulcer
prophylaxis) [1]. Consequently, the ICU population has
one of the highest occurrence rates of (nosocomial)
infections (20-30% of all ICU-admissions) [2,3], leading
to an enormous impact on morbidity, hospital costs,
and often, survival [4-6]. According to the EPIC II 1-day
prospective point-prevalence study (Extended Prevalence
of Infection in Intensive Care) in 1,265 participating
ICUs (75 countries worldwide), 51% of the 12,796
patients were considered infected, although no subdivi-
sion was made for hospital-acquired infections [7].
Along with the problem of nosocomial infection goes
the burden of “multidrug” antimicrobial resistance
(MDR). The ongoing emergence of resistance in the
community and hospital is considered a major threat for
public health. Due to the specific risk profile of its resi-
dents, the ICU also is deemed the epicenter of resistance
development. The ICU has even been described as a fac-
tory for creating, disseminating, and amplifying antimi-
crobial resistance [8]. Both infection and MDR result in
a considerable clinical and economic burden. As such,
the presence of MDR boosts the deleterious impact of
nosocomial infection [9]. Compared with infections not
caused by MDR microorganisms, the additional cost of
multidrug resistance in hospitalized patients with infec-
tions has been estimated at $6,000 to $30,000 (per
patient) [10]. This burden of resistance, however, is
probably more due to the higher rate of inappropriate
empiric antimicrobial treatment associated with infec-
tions caused by MDR pathogens than with the virulence
of particular MDR strains [11]. Yet, several studies ana-
lyzed the attributable mortality of MDR in some of the
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most important nosocomial pathogens, such as S. aur-
eus, Enterococci, Pseudomonas spp., Acinetobacter spp.
etc. [9]. Even when mortality figures were adjusted for
confounding factors, such as disease severity, exposure
time, underlying diseases, etc., mortality increased (up
to fivefold) when the causal organisms were MDR
[9,12,13].
Spread of multidrug resistance
The emergence of MDR often is dedicated to excessive
use of broad-spectrum antimicrobial agents (more than
60% of all ICU patients receive antibiotics during their
stay [14]), but the epidemiology of MDR is much more
complex and multifactorial in nature. During the past
few decades, it appeared that some antibiotics have a
higher risk of promoting antimicrobial resistance, e.g.,
third-generation cephalosporins, vancomycin, imipenem,
and intravenous fluoroquinolones [8,15]. Other antibio-
tics have been used for decades and still barely caused
resistance (e.g., colistin). Bonten and Mascini recognized
four main forces behind the emergence and further
spread of MDR microorganisms [16]: 1) induction of
resistant stains; 2) selection of resistant strains; 3) intro-
duction of resistant strains; and 4) dissemination of
resistant strains. These alterable/relative forces should
be especially considered as incentives to tackle the
spread of antimicrobial resistance, especially because all
microorganisms have their own mechanism and flexibil-
ity to become resistant depending on their ideal envir-
onment to tackle antimicrobial efficacy [16].
Induction of resistant stains
Resistance of susceptible bacteria can occur during anti-
microbial treatment, e.g., by mutations [16]. Quinolone
and cephalosporin resistance in Enterobacter spp. may
arise through this mechanism, but it is very unlikely
that it causes methicillin or vancomycin resistance in S.
aureus or enterococci in a single patient [16].
Selection of resistant strains
Antimicrobial therapy may select and favor overgrowth
of preexisting resistant flora [16]. Therefore, it is impor-
tant to maintain the nonpathogenic (anaerobic) flora, e.
g., in the gastrointestinal tract, to prevent overgrowth of
gram-negative MDR microorganisms [16].
Introduction of resistant strains
The growing community reservoir of MDR microorgan-
isms also results in a rise of MDR microorganisms in
the ICU, especially for species, such as methicillin-resis-
tant S. aureus and vancomycin-resistant enterococci
[16]. Healthcare workers often are carriers but also can
be vectors (cross-transmission) [9,16]. In addition, an
increasing number of patients is already colonized with
resistant bacteria on admission in the ICU [16]. When
colonization pressure with resistant strains is above a
certain level, the risk of cross-transmission becomes
extremely high and very difficult to overcome (inoculum
effect) [8]. Thus, in countries with a high endemic level
of resistance (e.g., MRSA), there is a real risk of antibio-
tic “spiral” [8].
Dissemination of resistant strains
As in all microorganisms, suboptimal infection control
also facilitates the spread of MDR microorganisms [16].
Important resistant pathogens
During the past decades, a shift in the MDR dilemma
has been noted from gram-positive to gram-negative
bacteria, especially due to the scarceness of new antimi-
crobial agents active against resistant gram-negative
microorganisms [17]. Among gram-positive organisms,
the most important resistant microorganisms in the ICU
are currently methicillin-(oxacillin-)-resistant Staphylo-
coccus aureus, and vancomycin-resistant enterococci
[17,18]. In gram-negative bacteria, the resistance is
mainly due to the rapid increase of extended-spectrum
Beta-lactamases (ESBLs) in Klebsiella pneumonia,
Escherichia coli, and Proteus mirabilis; high level third-
generation cephalosporin Beta-lactamase resistance
among Enterobacter spp. and Citrobacter spp., and
MDR in Pseudomonas aeruginosa, Acinetobacter spp.,
and Stenotrophomonas maltophilia [18]. Together with
the rise of difficult-to-treat MDR infections, several
other types of infections become more difficult to treat,
whereof the anaerobic Clostridium difficile spp., and
fungal infections will be described briefly.
Methicillin-resistant Staphylococcus aureus (MRSA)
Although methicillin-resistant Staphylococcus aureus
(MRSA) is already dethroned as the most feared MDR
microorganism by the emerging MDR gram-negatives, it
remains difficult to eradicate. Being endemic in numer-
ous hospitals worldwide, MRSA is still among the most
important causes of hospital-associated bacterial infec-
tions [15]. The driving force of resistance in MRSA is
cross-contamination and admission of already colonised
patients to the ICU [12,16]. Due to resistance to several
other (beta-lactam) antimicrobials, treatment of MRSA
often relies on vancomycin [18]. Yet, transmission of
resistance plasmids from enterococci to staphylococci
resulted in an increase of high-level, vancomycin-resis-
tance among S. aureus [15,18]. The National Nosoco-
mial Infection Surveillance (NNIS) study reported a rise
of MDR in S. aureus from 3% in the early 1980s to 53%
at the beginning of the 21st century [9,19]. According to
the EPIC II study the percentage of methicillin-resistant
isolates of S. aureus was approximately 50% in Western
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and Eastern Europe, but approximately 65% in the
Americas [7]. The epidemiology of MRSA is extremely
sensitive to changes in admission prevalence and failures
in infection control, which are only partially influenced
by reductions in antibiotic use [16]. Previous stay in
hospital or long-term care facilities, ICU stay, intravas-
cular devices, prior or prolonged antibiotic therapy,
chronic underlying conditions, surgical wounds,
advanced age, and cross-contamination are the most
important risk factors for MRSA colonization and infec-
tion [15].
Vancomycin-resistant enterococci (VRE)
Enterococci have a remarkable ability to adapt to envir-
onmental changes and acquire antimicrobial resistance,
leading to multiple vancomycin-resistant phenotypes,
but also resistance to ampicillin, aminoglycosides, and
other beta-lactam antibiotics [18]. As in MRSA, cross-
contamination and admission of already colonized
patients to the ICU are important causes for the spread
of VRE [12,16]. In addition, VRE genes can be trans-
mitted to other species through plasmids [18]. Entero-
cocci also are among the most frequent causes of
hospital-acquired infections and the rise of VRE during
the past decades has been remarkable (from < 1-25%
since the early 1980s) [9,15,20]. According to the EPIC
II study, rates of vancomycin resistance among entero-
coccal isolates were approximately 33-40% in Western
Europe, Eastern Europe, and Asia but approximately
50% in the Americas and Oceania [7]. The rate of van-
comycin resistance varies among enterococcal spp., and
is highest in E. faecium, of which >80-85% also is resis-
tant to ampicillin and penicillin and >50% to high-level
gentamicin [21]. VRE favors the highly compromised
patient, with as most important independent risk factors
for VRE colonization or infection, previous antibiotic
exposure (vancomycin, cephalosporins, or agents with
anaerobic activity), enteral feeding, cross-contamination,
and prolonged hospital stay [15,22].
Enterobacteriaceae
In contrast to MRSA and VRE, for which a single anti-
biotic indicates the resistance phenotype of interest,
MDR is usually more difficult to define in gram-nega-
tive bacilli, due to cross-transmission of resistance char-
acteristics and the wide range of antimicrobials not
active against (most) gram-negative microorganisms
[18,22]. Resistance of gram-negative bacteria is conse-
quently emerging in the hospital setting, especially
through the production of extended spectrum beta-lac-
tamases (ESBLs), in particular by E. coli and Klebsiella
spp. and Proteus spp. [13,18,23,24]. ESBLs are plasmid-
mediated, and their potential for transfer makes effec-
tive control and treatment difficult, which has resulted
in endemic and epidemic outbreaks [23]. ESBLs were
first recognized in the early 1980s among K. pneumo-
niae in Europe, and its prevalence has increased drama-
tically in the ICUs and in the community (e.g., extended
care facilities), with now more than 500 different types
of beta-lactamases identified from clinical isolates
[21,25]. A decreasing efficacy in gram-negatives of
third-generation cephalosporins, carbapenems, and
fluoroquinolones has been described [18,21]. The devel-
opment of quinolone resistance needs only two muta-
tions, e.g., expression of inducible cephalosporin-
resistance in Enterobacter spp. [16]. Especially the pro-
duction of Klebsiella pneumonia carbapenemase (KPC)
by Enterobacteriaceae becomes problematic, because
KPC beta-lactamases result in decreased susceptibility
or resistance to virtually all beta-lactam antibiotics; and
many strains of Enterobacteriaceae were already resis-
tant to a wide range of non-beta-lactam antibiotics [26].
Since 2000, the already ubiquitous E. coli has emerged
as major ESBL producing organism. In contrast to Kleb-
siella spp., which is usually involved in nosocomial/ICU
infections, ESBL-producing E. coli appeared more fre-
quently in community-acquired infections, especially in
certain areas in Asia [25]. In 2007, already 79% of E. coli
isolates collected in India, were positive for ESBLs, with
an almost identical prevalence in both hospital and
community [25,27].
Reported risk factors for infection/colonisation with
ESBL are prior use of antimicrobials, ICU stay, indwel-
ling devices, increased illness-severity, prolonged (ICU-)
hospitalization, emergency intra-abdominal surgery,
mechanical ventilation, and residence in nursing homes
[21,25].
Pseudomonas/Acinetobacter
Nosocomial isolated strains of Pseudomonas and Acine-
tobacter spp., are frequently resistant to a broad range
antibiotics. Their prevalence appears to be increasing
worldwide, especially as cause of ventilator-associated
pneumonia or in high-risk populations, such as patients
with severe burn injury [22,28]. The respiratory tract is
the most important source of Pseudomonas isolates, fol-
lowed by wounds, urine, and the bloodstream [21].
Pseudomonas is intrinsically resistant to most antibiotics;
most active agents are carbapenems, piperacillin, cefe-
pime, ceftazidime, ciprofloxacin, amikacin, and tobramy-
cin [21]. Antimicrobial resistance develops rapidly under
selection pressure, and multiple mechanisms are respon-
sible: (hyper-)production of enzymes, such as beta-lacta-
mases and DNA-gyrases, active efflux pumps, and
permeability changes [21]. The NNISS study showed
27% fluoroquinolone-resistance in Pseudomonas isolates
in the ICU and 18% to imipenem [19]. Furthermore,
cross-resistance between fluoroquinolones and other
antibiotic agents, such as piperacillin-tazobactam, cefta-
zidime, and tobramycin is a frequent problem [21,29].
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Acinetobacter spp. are inheritably resistant to cepha-
losporins, penicillin’s, and aminoglycosides, and espe-
cially cause opportunistic infections in critically ill
patients [21]. Some strains of A. baumannii have been
detected that are resistant to all antibiotics [21,30]. They
rarely cause community-acquired infections and are
more common in tropical countries [21].
Clostridium difficile
Clostridium difficile spp. are among the most difficult
microorganisms to eradicate in the environment [31].
Its’ spores cannot be destroyed by antiseptics, such as
alcohol, so hand washing with water and soap is essen-
tial. Disease severity ranges from mild diarrhea to fulmi-
nant pseudo-membranous colitis; Clostridium spp. are
actually responsible for almost all antibiotic-associated
pseudo-membranous colitis [32]. The incidence is rather
low although rising, and several outbreaks have been
described [31]. Due to a reduced susceptibility to metro-
nidazole, antibiotic treatment also becomes more diffi-
cult [33]. Most important risk factors for Clostridium-
associated diarrhoea antimicrobial therapy, older age
(>65 years), antineoplastic chemotherapy, and length of
hospital stay [32]. Other interventions with high-risk
associations are enemas, nasogastric tubes, gastrointest-
inal surgery, and antiperistaltic drugs [32].
Candida infections
Due to their immunocompromised status, patients in
the ICU are at risk of invasive candidiasis [34,35]. The
problem of MDR in candidiasis merely results from a
shift in etiology from mainly C. albicans to non-albicans
spp., such as the intrinsically fluconazole-resistant C.
krusei or the dose-dependent susceptible C. glabrata
[36]. Leroy et al. found that almost half of the invasive
candida infections in the ICU (N = 300) were due to
non-albicans species and reduced susceptibility to fluco-
nazole was observed in 17% of all Candida isolates [37].
A prospective study on candidemia of the same authors
(N = 135) failed to find pertinent risk factors predicting
non-albicans spp. [38], although two other studies
found an association between non-albicans candidemia
and azole treatment [36], female gender [39], and also
with (duration of) the use of central venous catheters
[36,39].
Resistance in the ICU and abroad
Although the ICU can be considered as the epicenter of
MDR, the past decades a notable shift has taken place
to general wards, nursing homes, and even the broader
community. The European Antimicrobial Resistance
Surveillance System (EARSS), which collected data on
antimicrobial resistance in spinal fluid and blood sam-
ples in 31 countries, showed a wide variation in MDR
among and within different countries [40]. Especially
MRSA continues to spread, although a stabilization (or
even decrease) is noted in high endemic countries. How-
ever, such data are generally limited to hospital settings,
whereas the total burden of MRSA in the broader com-
munity remains a blind spot. Besides MRSA, VRE, and
the MDR Enterobacteriaceae (in particular E. faecium
and E. coli) remain important challenges for infection
control [40].
Infection control measures have important implica-
tions for daily practice, because more and more patients
are already colonised or infected with MDR microorgan-
isms on arrival in the ICU [41]. Therefore, broad
empiric coverage may be needed in several patients; in
particular those patients with prolonged hospitalizations
(not only ICU). Until several years ago, this strategy was
only needed for patients with classic risk factors for
MDR, namely >1 week in ICU, and previous exposure
to antimicrobial agents. A recent Belgian multicenter
study showed that these classic risk factors lost their
predictive value as in 40% of infected patients without
risk factors; the causative pathogen was MDR [41].
Solutions?
Because the pipeline of new antibiotics is running dry
[17], major efforts are needed to slow down the rising
problem of MDR. The Centres for Disease Control
recommends four strategies for health care settings: 1)
prevent infections; 2) diagnose and treat infections; 3)
prudent and rational use of antimicrobials; and 4) pre-
vent transmission [8,9]. Joined efforts of healthcare pro-
viders, hospital administrators, policy makers, and
patients will certainly be necessary (up to an interna-
tional level) to reduce and optimize the overall antibiotic
consumption. This should especially affect those most
vulnerable patients, at highest risk for fatal outcomes,
namely those in the ICU, because local efforts limited to
the ICU will have too little impact. “Antibiotic steward-
ship,” or the optimization of antibiotic usage for therapy
and prophylaxis, is certainly a keystone to tackle this
problem [42,43].
Yet, there is a wide variation in current practice, par-
tially due to a lack in evidence on the best strategies to
cope with prevention of infection and spread of MDR.
Although several measures in infection control are
widely accepted, hand hygiene for example, there exist
some controversy about others, mostly more complex
interventions. Frequently infection prevention measures
are subject to a debate that is concentrated on the trian-
gle: economic issues vs. health vs. evidence [44]. Restric-
tion of antibiotic consumption by a sensible hospital
drug policy and promotion of a more rational use of
antibiotics should halt the rising of MDR [42]. There-
fore, additional efforts are needed to improve education
and training, for example, by implementing guidelines in
infection control and antibiotic prescription. Yet,
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surveillance and monitoring of trends in MDR, with
timely updates of local susceptibility data, should be
implemented as well [42,43].
In the battle against MDR, several behavioral changes
have been proposed to reduce or to improve antimicro-
bial therapy in community, long-term care facilities, and
hospitals. In the ICU-specific strategies, such as antimi-
crobial cycling and de-escalation schemes have been
proposed, although there often is a strident contrast
between evidence and expert opinion [45,46]. Even the
high ("standard”) use of antimicrobials in the ICU has
been questioned lately [44]. Especially in ICU patients
with severe sepsis, use of wide-spectrum antibiotics is
believed to be necessary, because these patients are sup-
posed to have little margin for error in choice of ther-
apy. Therefore, the initial selection of antibiotics should
cover all likely pathogens [44]. Peculiarly, even this
hypothesis is based on only a few studies, usually retro-
spective. This stands in contrast to high levels of “inap-
propriate” early antibiotic therapy, which does not
always lead to tremendously increased mortality rates
[47].
When it concerns prescription of antibiotic therapy,
the clinician must balance between optimizing the odds
of survival for the individual patient and minimizing the
microbial selection pressure. A study of Lipsitch et al.
[46] concluded that “use of an antibiotic for which resis-
tance is not present will be positively associated at the
individual level with carriage of bacteria resistant to
another antibiotic but negatively associated at the popu-
lation level with the prevalence of resistance to the other
antibiotic”. Routine surveillance cultures to steer empiric
antibiotic therapy may result in higher rates of initial
appropriate therapy while including a substantial poten-
tial in the savings of last-line antibiotic agents [8,48].
Another practice that clearly showed to be beneficial in
several studies is selective digestive decontamination,
also in reducing the overall number of infections
[49-52]. This technique mainly eradicates potentially
pathogenic gram-negative aerobic bacteria in the gastro-
intestinal tract through a combination of enteral and
parenteral antimicrobial therapy. This approach is
steered by additional efforts in infection control, includ-
ing the use of routine surveillance cultures. Several stu-
dies showed clear benefit [51], but despite this, only a
few hospitals adopted this strategy in daily practice. A
drawback of selective digestive decontamination is that
it may promote overgrowth of MDR gram-positive bac-
teria, such as MRSA. As such, it is preferably used in
setting with a very low baseline prevalence of MRSA
[53].
Thus, species-specific impact of preventive measures
certainly depends on the local epidemiology and resis-
tance levels. Therefore, prevention programs should be
tailored to the local epidemiology and organized hospi-
tal-wide and not only localized to the ICU [8]. A team
approach should be preferred, including ICU physi-
cians and nurses, but also the infection control team,
and the team especially needs a strong cooperation
with infectious disease specialists and clinical micro-
biology teams [54-56]. Several care bundles, or
“packages of interventions,” have been promoted
instead of single efforts to prevent infections, although
these care bundles are rarely based on solid evidence
[44].
Conclusions
Infections due to MDR microorganisms are a rising pro-
blem, especially in the ICU where even sensitive patho-
gens already cause additional morbidity, mortality, and
hospital costs. Therefore, additional efforts are needed
in the future to win this battle. Constant evaluation of
current practice on basis of trends in MDR and antibio-
tic consumption patterns is essential to make progress
in this problematic matter.
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